<DOC>
	<DOCNO>NCT00002800</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Combining one drug may kill cancer cell . PURPOSE : Phase II trial study effectiveness high-dose cytarabine plus idarubicin treating patient newly diagnose acute chronic myelogenous leukemia myelodysplastic syndrome .</brief_summary>
	<brief_title>Chemotherapy Treating Patients With Newly Diagnosed Acute Chronic Myelogenous Leukemia Myelodysplastic Syndrome</brief_title>
	<detailed_description>OBJECTIVES : I . Evaluate effect combine intensive induction postremission therapy high-dose cytarabine plus single high dose idarubicin patient previously untreated acute myelogenous leukemia ( AML ) . II . Identify cytogenetic , molecular , immunophenotypic marker AML patient use study residual disease . OUTLINE : All patient receive high dose cytarabine 5 day idarubicin third day induction chemotherapy . Patients achieve complete remission ( CR ) proceed consolidation chemotherapy , follow : cytarabine etoposide 5 day ; , patient age 60 , cytarabine 4 day , idarubicin third day . Patients eligible second consolidation course may peripheral blood stem cell collect follow regimen . Patients HLA-compatible donor proceed allogeneic bone marrow transplantation , patient age 60 , ( 8 ; 21 ) inv16 cytogenetic abnormality , without HLA-compatible donor receive maintenance therapy humanize monoclonal antibody M195 twice weekly 3 week , monthly 5 month . G-CSF administer chemotherapy regimen . Patients follow survival . PROJECTED ACCRUAL : 60 patient enter 3 year .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Idarubicin</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow hematologic malignancy ineligible high priority protocol confirm Memorial Hospital : Acute myelogenous leukemia Accelerated blastic phase ( great 10 % blast marrow ) chronic myelogenous leukemia Poorrisk myelodysplastic syndrome , define : Refractory anemia excess blast ( RAEB ) least 10 % marrow blast cytopenia require therapy RAEB transformation Chronic myelomonocytic leukemia No acute promyelocytic leukemia PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Hematopoietic : Not specify Hepatic : Bilirubin great 2.0 mg/dL Transaminases great 3 time normal Renal : Creatinine great 2.0 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No cardiomyopathy No symptomatic congestive heart failure Other : No concurrent active malignancy No pregnant nursing woman PRIOR CONCURRENT THERAPY : No prior therapy except biologic agent alone hydroxyurea</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2013</verification_date>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia excess blast transformation</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>neutropenia</keyword>
</DOC>